Agendia is a commercial-stage molecular diagnostics company specializing in oncology, with a primary focus on breast cancer. They develop and market proprietary genomic profiling tests that provide critical insights into a patient's tumor biology. These tests, including the flagship MammaPrint® (a 70-gene breast cancer recurrence assay) and BluePrint® (an 80-gene molecular subtyping assay), help physicians make more informed and personalized treatment decisions. Agendia aims to improve patient outcomes, reduce the risk of over- or under-treatment, and advance the standard of care in breast cancer management worldwide.
The Irvine headquarters serves as the primary hub for Agendia's US operations, encompassing commercial activities, strategic partnerships, research and development collaborations, and administrative functions for the Americas region.
The facility includes modern office spaces and advanced laboratory capabilities compliant with CLIA (Clinical Laboratory Improvement Amendments) and other relevant regulatory standards, designed to support cutting-edge molecular diagnostics.
Agendia fosters a dynamic and science-driven work culture. It emphasizes innovation, collaboration, and a patient-centric approach, with employees dedicated to making a tangible impact in the field of oncology.
Located in a prominent Southern California biotech hub, the Irvine headquarters benefits from access to a rich talent pool, leading research institutions, and a vibrant life sciences ecosystem, crucial for Agendia's growth and market presence in the US.
Agendia has a robust global presence, with its genomic tests for breast cancer utilized by healthcare professionals in numerous countries across North America, Europe, Asia, and other regions. Key functions supported globally include sales and marketing, distribution, customer and medical support, operation of its high-complexity laboratories in the US and Netherlands for sample processing, extensive international research collaborations, and the management of clinical trials to further validate and expand the utility of its diagnostic solutions worldwide.
22 Morgan
Irvine
CA
USA
Address: Science Park 406, 1098 XH Amsterdam, The Netherlands
Manages and supports Agendia's operations across the EMEA region and beyond, including clinical collaborations, regulatory affairs, market access initiatives, and customer support for oncologists and healthcare providers utilizing Agendia's genomic assays.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Agendia' leadership includes:
Agendia has been backed by several prominent investors over the years, including:
In the past 12 months, Agendia has made significant additions to its executive leadership team, appointing a new Chief Financial Officer, Chief Commercial Officer, and Chief Operations Officer. These strategic hires are aimed at driving the company's growth, commercial expansion, and operational efficiency in the competitive molecular diagnostics landscape.
Discover the tools Agendia uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Agendia's most commonly observed email format combines the employee's first initial with their full last name, followed by the '@agendia.com' domain. For example, an employee named Jane Doe would likely have an email address like 'jdoe@agendia.com'. While other formats might be used internally, this is the primary pattern for external communications.
[first_initial][last]@agendia.com
Format
mstraley@agendia.com
Example
75%
Success rate
Business Wire • May 2, 2024
Agendia announced its plans to present new data highlighting the clinical utility of its MammaPrint® and BluePrint® genomic tests at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will focus on how these tests aid in personalizing treatment strategies for patients with early-stage breast cancer, including their effectiveness in diverse patient populations and specific cancer subtypes....more
Business Wire • January 10, 2024
Agendia announced the appointment of Dale G. Naticchia as its new Chief Operations Officer. Naticchia brings substantial experience in operations, manufacturing, and supply chain management within the diagnostics and life sciences industries. His role will focus on scaling Agendia's global operations to support the company's growth and market expansion....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Agendia, are just a search away.